Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
J Pediatr Urol ; 14(2): 161.e1-161.e8, 2018 04.
Article in English | MEDLINE | ID: mdl-29133167

ABSTRACT

INTRODUCTION: There is controversy about the role of lymph node (LN) sampling or dissection in the management of favorable histology (FH) Wilms tumor (WT), specifically how it performed and how it may impact survival. OBJECTIVE: The objective of this study was to analyze factors affecting LN sampling patterns and the impact of LN yield and density (number of positive LNs/LNs examined) on overall survival (OS) in patients with advanced-stage favorable histology Wilms tumor (FHWT). METHODS: The National Cancer Database (NCDB) was queried for patients with FHWT during 2004-2013. Demographic, clinical and OS data were abstracted for those who underwent surgical resection. Poisson regression was performed to analyze how factors influenced LN yield. Patients with positive LNs had LN density calculated and were further analyzed. RESULTS: A total of 2340 patients met criteria, with a median age at diagnosis of 3 years (range 0-78 years). The median number of LNs examined was three (range 0-87). Lymph node yield was affected by age, race, insurance, tumor size, laterality, advanced stage, LN positivity, and institutional volume. A total of 390 (16.6%) patients had LN-positive disease. Median LN density for these LN-positive patients was 0.38 (range 0.02-1) (Summary Figure). Estimated 5-year OS was significantly improved for those with LN density ≤0.38 vs. >0.38 (94% vs. 84.6%, P = 0.012). In this population, on multivariate analysis, age and LN density were significant predictors of OS. DISCUSSION: It is difficult to compile large numbers of cases in rare diseases like WT, and fortunately a large administrative database such as the NCDB can serve as a great resource. However, administrative data come with inherent limitations such as missing data and inability to account for a variety of factors that may influence LN yield and/or OS (specimen designation, pathologist experience, surgeon experience/volume, institutional Children's Oncology Group (COG) association, etc.). In this specific disease, the American Joint Committee on Cancer staging (captured by the NCDB) is different than the COG WT staging system that is used clinically, and the NCDB does not capture oncologic outcomes beyond OS. CONCLUSIONS: In a review of the NCDB, various factors associated with LN yield and observed LN density were identified to be significantly associated with OS in patients with LN-positive FHWT. This reinforces the need for adequate LN sampling at the time of WT surgery, to maximize surgical disease control. It was proposed that LN density as a metric may allow for improved risk-stratification, and possibly allow for therapeutic reduction in a sub-set of patients with low LN density.


Subject(s)
Kidney Neoplasms/mortality , Kidney Neoplasms/pathology , Lymph Node Excision/statistics & numerical data , Lymph Nodes/pathology , Wilms Tumor/mortality , Wilms Tumor/pathology , Adolescent , Adult , Age Factors , Aged , Analysis of Variance , Child , Child, Preschool , Databases, Factual , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Kidney Neoplasms/surgery , Male , Middle Aged , Multivariate Analysis , Neoplasm Invasiveness/pathology , Neoplasm Staging , Prognosis , Retrospective Studies , Risk Assessment , Sex Factors , Survival Analysis , United States , Wilms Tumor/surgery , Young Adult
2.
Cancer Res ; 61(9): 3591-4, 2001 May 01.
Article in English | MEDLINE | ID: mdl-11325825

ABSTRACT

Histone deacetylase inhibitors (HDACIs) inhibit the growth of a variety of transformed cells in culture. We demonstrated previously that the hybrid-polar HDACI m-carboxycinnamic acid bis-hydroxamide (CBHA) induces apoptosis of human neuroblastoma in vitro and is effective in lower doses when combined with retinoids. The current study investigates the effect of CBHA on the growth of human neuroblastoma in vivo, both alone and in combination with all-trans retinoic acid (atRA), using a severe combined immunodeficiency-mouse xenograft model. CBHA (50, 100, and 200 mg/kg/day) inhibited growth of SMS-KCN-69n tumor xenografts in a dose-dependent fashion, with 200 mg/kg CBHA resulting in a complete suppression of tumor growth. The efficacy of 50 and 100 mg/kg CBHA was enhanced by the addition of 2.5 mg/kg atRA. This dose of atRA was ineffective when administered alone. Treatment was accompanied by mild weight loss in all groups except the lowest dose of CBHA. Our results suggest HDACIs alone or combined with retinoids may have therapeutic utility for neuroblastoma.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Cinnamates/pharmacology , Enzyme Inhibitors/pharmacology , Neuroblastoma/drug therapy , Tretinoin/pharmacology , Acetylation , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/toxicity , Antineoplastic Combined Chemotherapy Protocols/toxicity , Cell Division/drug effects , Cinnamates/administration & dosage , Cinnamates/toxicity , Dose-Response Relationship, Drug , Drug Synergism , Enzyme Inhibitors/toxicity , Female , Growth Inhibitors/pharmacology , Histone Deacetylase Inhibitors , Histones/metabolism , Humans , Mice , Mice, SCID , Neuroblastoma/enzymology , Neuroblastoma/pathology , Tretinoin/administration & dosage , Tumor Cells, Cultured , Weight Loss/drug effects , Xenograft Model Antitumor Assays
3.
Med Pediatr Oncol ; 35(6): 577-81, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11107121

ABSTRACT

BACKGROUND: Neuroblastoma is a common childhood cancer with a poor overall prognosis. Retinoic acids (RAs) have been studied as a potential therapy, showing promise in recurrent disease. The histone deacetylase inhibitor (HDACI) M-carboxycinnamic acid bishydroxamide (CBHA) is another potential therapy, which we recently described. Combinations of RAs and HDACIs currently under investigation display synergy in certain neoplasms. In this study, we evaluate the effect of combinations of RAs and HDACIs on human neuroblastoma cells. PROCEDURE: Established cell lines were cultured in increasing concentrations of HDACIs, RAs, and combinations thereof. Following exposure, viable cell number was quantified by trypan blue dye exclusion on a hemacytometer. Cell cycle analysis was performed by propidium iodide staining and FACS. RESULTS: All assayed HDACIs and RAs decreased viable cell number. Lower concentrations of each agent were effective when the two were combined. The primary reason for decreased cell number appears to be apoptosis following HDACI exposure and G1 arrest following RA exposure. Both effects are seen with cotreatment. Caspase inhibition abrogates the apoptotic response. CONCLUSIONS: CBHA causes apoptosis of human neuroblastoma in vitro, an effect that can add to the effects of RA. HDACIs and RAs inhibit neuroblastoma in significantly lower concentrations when used together than when used individually. Combination therapy may improve the ultimate efficacy while reducing the side effects of these agents in clinical use.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cinnamates/therapeutic use , Histone Deacetylase Inhibitors , Neuroblastoma/drug therapy , Neuroblastoma/pathology , Tretinoin/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Apoptosis/drug effects , Caspase Inhibitors , Cell Division/drug effects , Cinnamates/pharmacology , G1 Phase/drug effects , Humans , Tretinoin/pharmacology , Tumor Cells, Cultured
4.
J Pediatr Surg ; 35(9): 1356-8, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10999698

ABSTRACT

Extraosseous Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET) is a rare soft tissue tumor of childhood usually found in the extremities. The authors present the case of a 17-year-old girl who presented with right flank pain and hematuria and during operation was found to have a right ureteral mass. The histopathologic, immunohistochemical, ultrastructural, and cytogenetic characteristics of the excised mass were consistent with extraosseous ES/PNET. This is the first known reported case of extraosseous ES/ PNET of the ureter. The pathologic features and clinical management of this case, as well as a review of the literature, are presented.


Subject(s)
Neuroectodermal Tumors, Primitive, Peripheral , Sarcoma, Ewing , Ureteral Neoplasms , Adolescent , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chromosomes, Human, Pair 11 , Chromosomes, Human, Pair 22 , Combined Modality Therapy , Female , Humans , Neuroectodermal Tumors, Primitive, Peripheral/genetics , Neuroectodermal Tumors, Primitive, Peripheral/pathology , Neuroectodermal Tumors, Primitive, Peripheral/surgery , Sarcoma, Ewing/genetics , Sarcoma, Ewing/pathology , Sarcoma, Ewing/surgery , Translocation, Genetic , Ureteral Neoplasms/genetics , Ureteral Neoplasms/pathology , Ureteral Neoplasms/surgery
5.
J Pediatr Surg ; 35(4): 627-9, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10770401

ABSTRACT

A 4-year-old boy presented with a duodenal hematoma and was admitted for conservative management including nasogastric tube drainage and parenteral nutrition. Within 2 days, the child became fungemic and went on to require urgent laparotomy. This previously undescribed life-threatening complication of duodenal hematoma is discussed in the context of standard treatment of this injury.


Subject(s)
Candidiasis/etiology , Duodenal Diseases/complications , Hematoma/complications , Jejunal Diseases/complications , Abdominal Injuries/complications , Child, Preschool , Duodenal Diseases/diagnostic imaging , Duodenal Diseases/surgery , Hematoma/diagnostic imaging , Hematoma/surgery , Humans , Jejunal Diseases/surgery , Male , Tomography, X-Ray Computed
6.
J Pediatr Surg ; 35(3): 465-72, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10726691

ABSTRACT

BACKGROUND/PURPOSE: Neuroblastoma is the most solid common extracranial malignancy in childhood. Despite multimodality treatment, high-risk disease continues to carry a poor prognosis. Glucocorticoids have been shown previously to induce differentiation in murine neuroblastoma cell lines, but no such effect has been documented in human neuroblastoma cells. Glucocorticoids are known to be active in the differentiation process of the neural crest. These studies describe the effects of dexamethasone on 6 human neuroblastoma cell lines. METHODS: Dexamethasone was added to cultured neuroblastoma cell lines (LA1-5S, LA1-15N, BE[2]S, BE[2]N, SH-EP-1, SH-SY5Y) maintained in media supplemented with either normal serum or charcoal-depleted serum. Proliferation assays were performed, and flow cytometry was used to assess alterations in cell cycle. Cells were closely monitored for morphological changes with serial phase-contrast microscopy. Immunohistochemistry (3F8, NF-1, TRK-A) of cultured cells was used to evaluate differentiation. Glucocorticoid receptor levels was assessed using immunoblotting. RESULTS: Dexamethasone decreased the rate of cellular proliferation in both standard and charcoal-depleted conditions. Flow cytometry showed a G1 accumulation. Increased expression of the differentiation-associated antigens was found in cells cultured in charcoal-depleted media, and a further augmentation was seen with the addition of dexamethasone. In standard media, dexamethasone had no detectable effect on the expression of these antigens. Glucocorticoid receptor expression was found to be comparable in all cell lines. CONCLUSIONS: Human neuroblastoma cells are sensitive to the differentiating effects of dexamethasone in an environment of charcoal-depleted serum. This phenomenon may be caused by the existence of growth and mitogenic factors in serum that are inhibiting differentiation.


Subject(s)
Antineoplastic Agents, Hormonal/pharmacology , Cell Differentiation/drug effects , Cell Division/drug effects , Dexamethasone/pharmacology , Neuroblastoma/pathology , Humans , Immunohistochemistry , In Vitro Techniques , Neuroblastoma/drug therapy , Prognosis , Receptors, Glucocorticoid/analysis , Tumor Cells, Cultured/drug effects
7.
J Pediatr Surg ; 35(2): 303-7; discussion 308, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10693685

ABSTRACT

BACKGROUND/PURPOSE: Extended left hepatectomy, also referred to as left hepatic trisegmentectomy, in which segments II, III, IV, V, and VIII are excised, is rarely performed in children. Experience with 7 such resections is reported to describe the anatomy, technique, indications, and outcomes of the operation. METHODS: The medical records of all pediatric patients treated at our institution over the last 15 years who underwent extended left hepatectomy were reviewed. Demographic information as well as operative, pathological, and follow-up data were analyzed. RESULTS: Seven patients underwent extended left hepatectomy over this period. There were 5 boys and 2 girls ranging in age between 4 months and 9 years with a median age of 3.1 years. Follow-up ranged from 8 months to 5 years with a median of 3.5 years. Diagnoses included hepatoblastoma (HB, n = 3), focal nodular hyperplasia (FNH, n = 1), leiomyosarcoma (LMS, n = 1), hepatocellularcarcinoma (HCC, n = 1), and metastatic neuroblastoma (NB, n = 1). All surgical margins were grossly negative. Median operative blood loss was 13 mL/kg (range, 5 to 32 mL/kg), and mean hospital stay was 9 days (range, 7 to 12 days). No major intra- or postoperative complications were encountered, and there was no perioperative mortality. The 3 HB patients, 1 FNH patient, 1 LMS patient, and 1 NB patient are without evidence of disease, whereas the 1 child with HCC died of recurrent and distant disease. The 6 surviving children have normal hepatic function. CONCLUSION: Although technically challenging and rarely performed, extended resection of the left hepatic lobe is feasible in children and can yield curative results with minimal morbidity.


Subject(s)
Hepatectomy/methods , Hepatoblastoma/surgery , Liver Neoplasms/surgery , Carcinoma, Hepatocellular/surgery , Child , Child, Preschool , Female , Ganglioneuroblastoma/surgery , Humans , Infant , Leiomyosarcoma/surgery , Male , Retrospective Studies
8.
Cancer Res ; 59(17): 4392-9, 1999 Sep 01.
Article in English | MEDLINE | ID: mdl-10485488

ABSTRACT

Inhibitors of histone deacetylase (HDAC) have been shown to have both apoptotic and differentiating effects on various tumor cells. M-carboxycinnamic acid bishydroxamide (CBHA) is a recently developed hybrid polar compound structurally related to hexamethylene bisacetamide. CBHA is a potent inhibitor of HDAC activity. CBHA induces cellular growth arrest and differentiation in model tumor systems. We undertook an investigation of the effects of CBHA on human neuroblastoma cell lines in vitro. When added to cultures of a panel of neuroblastoma cell lines, CBHA induced the accumulation of acetylated histones H3 and H4, consistent with the inhibition of HDAC. Concentrations of CBHA between 0.5 microM and 4 microM led to apoptosis in nine of nine neuroblastoma cell lines. Apoptosis was assessed by DNA fragmentation analysis and the appearance of a sub-G1 (<2N ploidy) population by flow cytometric analysis. The addition of a caspase inhibitor (benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone) completely abrogated CBHA-induced apoptosis in three of three cell lines. The addition of cycloheximide greatly reduced CBHA-induced apoptosis, suggesting that apoptotic induction was dependent on de novo protein synthesis. In addition, CBHA induced the expression of both CD95 (APO-1/Fas) and CD95 ligand within 12 h. The effect of CBHA on human neuroblastoma cells suggests that this agent and structurally related synthetic hybrid polar compounds have therapeutic potential for the treatment of this malignancy.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cinnamates/pharmacology , Enzyme Inhibitors/pharmacology , Histone Deacetylase Inhibitors , Membrane Glycoproteins/biosynthesis , Neuroblastoma/drug therapy , fas Receptor/biosynthesis , Caspase Inhibitors , Cell Division/drug effects , Cell Nucleus/drug effects , Cycloheximide/pharmacology , DNA Fragmentation/drug effects , Fas Ligand Protein , Histones/metabolism , Humans , Neuroblastoma/metabolism , Neuroblastoma/pathology , Tumor Cells, Cultured
9.
J Pediatr Surg ; 34(6): 1000-3, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10392922

ABSTRACT

BACKGROUND/PURPOSE: Although there has been a precedent of testicular-sparing surgery in some centers, the authors find it is still not general practice among pediatric surgeons. To address this and emphasize the role of testicular-sparing surgery in children, four patients with testicular masses are presented who underwent this procedure. METHODS: Four patients who underwent testicular-sparing surgery between the years 1993 and 1998 were reviewed. Demographic data, histopathology, and follow-up data were obtained from office charts. The period of follow-up ranged from 1 to 5 years. RESULTS: Four patients whose ages at diagnosis were 1, 2, 4, and 17 years presented with unilateral testicular masses. The alpha-fetoprotein and beta-human chorionic gonadotropin levels were within normal limits. Testicular ultrasonography was carried out on all patients, and groin exploration with spermatic cord isolation was performed in each case. After enucleation, frozen sections to confirm benignity was carried out before repair of the testis. Follow-up of 6 months to 5 years has shown no recurrence, and on examination, testicular volume is normal in all cases. CONCLUSIONS: Testicular-sparing surgery preserves testicular volume, which is important for both cosmetic and functional purposes. It is a viable and useful method in the management of benign testicular tumors in children.


Subject(s)
Testicular Neoplasms/surgery , Adolescent , Biomarkers, Tumor , Child, Preschool , Frozen Sections , Humans , Infant , Male , Retrospective Studies , Testicular Neoplasms/blood , Testicular Neoplasms/diagnostic imaging , Testicular Neoplasms/pathology , Ultrasonography , Urologic Surgical Procedures, Male/methods
10.
J Pediatr Surg ; 34(4): 559-64, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10235322

ABSTRACT

BACKGROUND/PURPOSE: Mediastinal masses commonly are referred to the pediatric surgeon and can be difficult diagnostic problems. Various techniques have been used to perform biopsy in the mediastinum, but there are few reports of mediastinoscopy or Chamberlain procedure in children in the literature. The authors reviewed their experience with these techniques in a pediatric oncology population. METHODS: The medical records of all patients on the pediatric surgical service between 1987 and 1997, inclusive, who underwent mediastinoscopy or Chamberlain procedure were reviewed. Demographic data, diagnostic accuracy, complications, operating time, and blood loss were recorded. RESULTS: Sixteen consecutive patients underwent 13 Chamberlain procedures and six mediastinoscopies over the above period. Diagnostic accuracy was found to be 95% overall (100% for Chamberlain procedure, 83% for mediastinoscopy). Five complications occurred in the Chamberlain group and none in the mediastinoscopy group. No complication required thoracotomy or sternotomy. Among patients whose sole reason for admission was diagnosis of a mediastinal mass, the mean hospital stay was 1.7+/-0.8 days (n = 7) for those who underwent Chamberlain procedure and 1.4+/-0.9 days (n = 4) for those who underwent mediastinoscopy. One mediastinoscopy was performed as an ambulatory procedure. CONCLUSION: Mediastinoscopy and the Chamberlain procedure are effective and safe techniques for biopsy of mediastinal masses in this age group.


Subject(s)
Mediastinal Neoplasms/diagnosis , Adolescent , Biopsy , Child , Female , Hodgkin Disease/diagnosis , Hodgkin Disease/surgery , Humans , Length of Stay , Lymphoma, Non-Hodgkin/diagnosis , Lymphoma, Non-Hodgkin/surgery , Male , Mediastinal Neoplasms/surgery , Mediastinoscopy , Mediastinum/pathology , Mediastinum/surgery , Time Factors
11.
Semin Pediatr Surg ; 8(2): 69-77, 1999 May.
Article in English | MEDLINE | ID: mdl-10344303

ABSTRACT

Lymphomas are the most common cause of masses in the pediatric mediastinum. More than 50% of children with lymphoblastic lymphoma present with an anterior mediastinal mass, and more than one third of all patients with non-Hodgkin's lymphoma have their primary sites in the mediastinum. Hodgkin's disease also frequently involves this anatomic compartment with approximately two thirds of all pediatric cases manifesting mediastinal adenopathy. Although surgical resection generally is not involved in the primary treatment of these diseases, surgeons often play a key role in obtaining adequate tissue for proper diagnostic analysis. Surgical access to the mediastinum often is required in the acquisition of a specimen.


Subject(s)
Hodgkin Disease , Lymphoma, Non-Hodgkin , Mediastinal Neoplasms , Child , Hodgkin Disease/diagnosis , Hodgkin Disease/surgery , Humans , Lymphoma, Non-Hodgkin/diagnosis , Lymphoma, Non-Hodgkin/surgery , Mediastinal Neoplasms/diagnosis , Mediastinal Neoplasms/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...